Addendum: Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy
Metrics: PDF 101 views | ?
1HCG Manavata Cancer Centre, Nasik, Maharashtra, India
2Datar Cancer Genetics Limited, Nasik, Maharashtra, India
3Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India
4Department of Medical Oncology, Medical College Wisconsin, WI, USA
5Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, India
6Manipal Academy of Higher Education, Manipal, Karnataka, India
Published: November 2, 2022
Copyright: © 2022 Nagarkar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article has an addendum: The patient has previously consented to publication of de-identified findings.
Original article: Oncotarget. 2020; 11:4195–4200. DOI: https://doi.org/10.18632/oncotarget.27793
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.